Knowledge Hub
Knowledge Hub
Free, evidence-based resources for patients, families and health professionals navigating neuroendocrine cancer in Aotearoa New Zealand. Written in plain language, reviewed by clinicians.
Page 2 of 4
ToolNutrition guidance for managing unintended weight gain with NETs.
Read
ToolNutrition strategies for managing unintended weight loss with NETs.
Practical guide to advance care planning – conversations and documents that record what matters most to you and your whānau.
Read
Our monthly Zoom-In sessions with guest experts cover a vast array of topics of interest to neuroendocrine cancer patients, carers and healthcare…
Read
Living with NETs is a free online education programme designed for patients and support people navigating life with neuroendocrine tumors, whether you are…
Read
A first-in-human trial of [212Pb]VMT-α-NET, a targeted alpha-particle therapy for SSTR2-positive NETs, has reported early activity at ASCO GI 2026.
ReadNeuroendocrine tumours (NETs) is the umbrella term for a group of unusual, often slow-growing cancers.
Read
Our annual Patient Education Day is designed specifically for people living with Neuroendocrine Cancer (NETs), as well as their whānau, friends, and…
Read
We connect people living with neuroendocrine cancer through local and online peer-support catch-ups, creating a welcoming space to share experiences,…
Read
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
ReadA Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
ReadMobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Read
The CABINET trial led the FDA to approve cabozantinib in March 2025 for adults and adolescents with previously treated advanced pancreatic and extra-pancreatic NETs.
Read
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.
Read
ExternalCyclists on the 2025 Tour of New Zealand raised more than $18,000 for Neuroendocrine Cancer NZ.
Read
Sunday lunch? BBQ, picnic or pot luck? Let's NET Together and spread awareness about neuroendocrine Cancer on NET Cancer Day.
Read
ToolEditable invitation template for hosting your own Let's NET Together gathering on NET Cancer Day.
Read
ToolPrintable koha (donation) card for guests at your Let's NET Together event on NET Cancer Day.
Read
NECNZ founder and former CEO shares her NETs story
Read
Dave's NET story, part 2 – reflections fifteen years on from diagnosis, on living well with neuroendocrine cancer.
ReadThe Phase 3 NETTER-2 trial showed Lutathera plus octreotide nearly tripled progression-free survival when used as first-line therapy in grade 2/3 GEP-NETs.
ReadNeuroendocrine Cancer New Zealand mourns the passing of Associate Professor Dr Malcolm Legget, a tireless advocate for NET patients.
Read
VideoNETs are uncommon, so most GPs will never have managed a patient with one. There's a free RNZCGP-endorsed CME course you can ask them to take.
Read